This post discusses a Vioxx case, and Bexis’ tongue is thus tied. The following post was written by Herrmann alone:
Earlier this year, in a post cleverly titled, “Oy, Canada,” we deplored the fact that apparently no Canadian trial court had ever denied a motion to certify a class action.
We’re pleased to report that
A bill recently introduced in the New York State legislature proposes to eliminate the learned intermediary doctrine for prescription drugs or devices that are promoted through direct-to-consumer advertising. Here’s a link to the description of the bill.
A legal question that recently circulated on the defense counsel listserv for the Product Liability Advisory Council, Inc. (“PLAC”) drew a lot of attention, and thus strikes us as a good subject of discussion. That question was whether there’s authority allowing a product liability defendant to redact or otherwise keep confidential its customers’ contact information